Lecanemab in Early Alzheimer’s Disease
Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was...
Publications
View AllAffiliated Researchers
Institution Info
- Type
- healthcare
- Country
- JP
- Publications
- 1
- Citations
- 4,288
External Links
Identifiers
- ROR
- https://ror.org/02thzwy35